Living Tissue Technology
FDA-approved living skin substitutes containing human fibroblasts and keratinocytes for diabetic foot ulcers and venous leg ulcers. Apligraf and Dermagraft bioengineered skin grafts deliver growth factors, cytokines, and extracellular matrix proteins that promote rapid wound closure when standard treatments fail. Medicare Part B covered mobile wound care in Beverly Hills, Orange County, Los Angeles, and all Southern California.
Bioengineered skin substitutes are living tissue-engineered products that contain viable human cells (fibroblasts and/or keratinocytes) within a biocompatible matrix. These products mimic the structure and function of normal human skin.
Unlike traditional wound dressings, bioengineered skin actively participates in wound healing by secreting growth factors, cytokines, and extracellular matrix proteins that stimulate tissue regeneration and accelerate closure.
Contains viable human fibroblasts and keratinocytes
Rigorous clinical trials prove safety and efficacy
Reimbursed for qualifying chronic wounds
85%+ Healing Rate
In clinical studies
Bi-layered living skin equivalent with both dermal and epidermal layers
Cryopreserved human fibroblast-derived dermal substitute
Dehydrated human amnion/chorion membrane grafts
Porcine small intestinal submucosa extracellular matrix
Bilayer wound matrix for dermal regeneration
Split-thickness skin allograft with living cells
Living cells applied directly to wound bed
Cells secrete proteins that stimulate healing
Scaffold supports new tissue development
Host cells integrate graft and close wound
Our specialists will evaluate if you're a candidate for living tissue therapy
Schedule Evaluation